| Clinical Significance of Upregulation of EZH1 Expression in Hepatocellular Carcinoma Tissues. | Clinical Significance of Upregulation of EZH1 Expression in Hepatocellular Carcinoma Tissues.
Chen SY, Li JD, Huang ZG, He RQ, Chen F, Li JJ, Huang ZQ, Chen JT, Chen G, Dang YW. | 04/1/2024 |
| The competitive mechanism of EZH1 and EZH2 in promoting oral squamous cell carcinoma. | The competitive mechanism of EZH1 and EZH2 in promoting oral squamous cell carcinoma.
Chen J, Tang S, Zheng Q, Li J, Jiang H, Lu H, Liao G, Li K, Liang Y. | 03/6/2024 |
| Gain and loss of function variants in EZH1 disrupt neurogenesis and cause dominant and recessive neurodevelopmental disorders. | Gain and loss of function variants in EZH1 disrupt neurogenesis and cause dominant and recessive neurodevelopmental disorders.
Gracia-Diaz C, Zhou Y, Yang Q, Maroofian R, Espana-Bonilla P, Lee CH, Zhang S, Padilla N, Fueyo R, Waxman EA, Lei S, Otrimski G, Li D, Sheppard SE, Mark P, Harr MH, Hakonarson H, Rodan L, Jackson A, Vasudevan P, Powel C, Mohammed S, Maddirevula S, Alzaidan H, Faqeih EA, Efthymiou S, Turchetti V, Rahman F, Maqbool S, Salpietro V, Ibrahim SH, di Rosa G, Houlden H, Alharbi MN, Al-Sannaa NA, Bauer P, Zifarelli G, Estaras C, Hurst ACE, Thompson ML, Chassevent A, Smith-Hicks CL, de la Cruz X, Holtz AM, Elloumi HZ, Hajianpour MJ, Rieubland C, Braun D, Banka S, Genomic England Research Consortium, French DL, Heller EA, Saade M, Song H, Ming GL, Alkuraya FS, Agrawal PB, Reinberg D, Bhoj EJ, Martínez-Balbás MA, Akizu N., Free PMC Article | 07/13/2023 |
| Downregulation of the enhancer of zeste homolog 1 transcriptional factor predicts poor prognosis of triple-negative breast cancer patients. | Downregulation of the enhancer of zeste homolog 1 transcriptional factor predicts poor prognosis of triple-negative breast cancer patients.
Peng W, Tang W, Li JD, He RQ, Luo JY, Chen ZX, Zeng JH, Hu XH, Zhong JC, Li Y, Ma FC, Xie TY, Huang SN, Ge LY., Free PMC Article | 02/14/2023 |
| The role of EZH1 and EZH2 in development and cancer. | The role of EZH1 and EZH2 in development and cancer.
Lee SH, Li Y, Kim H, Eum S, Park K, Lee CH., Free PMC Article | 12/31/2022 |
| Polycomb EZH1 regulates cell cycle/5-fluorouracil sensitivity of neuroblastoma cells in concert with MYCN. | Polycomb EZH1 regulates cell cycle/5-fluorouracil sensitivity of neuroblastoma cells in concert with MYCN.
Shinno Y, Takenobu H, Sugino RP, Endo Y, Okada R, Haruta M, Satoh S, Mukae K, Shaliman D, Wada T, Akter J, Ando K, Nakazawa A, Yoshida H, Ohira M, Hishiki T, Kamijo T., Free PMC Article | 12/24/2022 |
| TRIM21 improves apatinib treatment in gastric cancer through suppressing EZH1 stability. | TRIM21 improves apatinib treatment in gastric cancer through suppressing EZH1 stability.
Ping M, Wang S, Guo Y, Jia J. | 01/15/2022 |
| Structures of monomeric and dimeric PRC2:EZH1 reveal flexible modules involved in chromatin compaction. | Structures of monomeric and dimeric PRC2:EZH1 reveal flexible modules involved in chromatin compaction.
Grau D, Zhang Y, Lee CH, Valencia-Sánchez M, Zhang J, Wang M, Holder M, Svetlov V, Tan D, Nudler E, Reinberg D, Walz T, Armache KJ., Free PMC Article | 02/20/2021 |
| Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas. | Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.
Yamagishi M, Hori M, Fujikawa D, Ohsugi T, Honma D, Adachi N, Katano H, Hishima T, Kobayashi S, Nakano K, Nakashima M, Iwanaga M, Utsunomiya A, Tanaka Y, Okada S, Tsukasaki K, Tobinai K, Araki K, Watanabe T, Uchimaru K. | 09/26/2020 |
| Findings highlight the role of EZH1 in non-histone lysine methylation, indicating that cooperation between AML1-ETO and EZH1 and AML1-ETO site-specific lysine methylation promote AML1-ETO transcriptional repression in leukemia. | Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia.
Dou L, Yan F, Pang J, Zheng D, Li D, Gao L, Wang L, Xu Y, Shi J, Wang Q, Zhou L, Shen N, Singh P, Wang L, Li Y, Gao Y, Liu T, Chen C, Al-Kali A, Litzow MR, Chi YI, Bode AM, Liu C, Huang H, Liu D, Marcucci G, Liu S, Yu L., Free PMC Article | 03/14/2020 |
| EZH1 mutations predominantly occurred in clinically benign follicular neoplasms without RAS mutations. | Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors.
Jung CK, Kim Y, Jeon S, Jo K, Lee S, Bae JS. | 10/26/2019 |
| functions mostly within canonical PRC2 and exhibits proliferation-dependent redundancy that shapes mutational signatures in cancer | EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
Wassef M, Luscan A, Aflaki S, Zielinski D, Jansen PWTC, Baymaz HI, Battistella A, Kersouani C, Servant N, Wallace MR, Romero P, Kosmider O, Just PA, Hivelin M, Jacques S, Vincent-Salomon A, Vermeulen M, Vidaud M, Pasmant E, Margueron R., Free PMC Article | 06/1/2019 |
| Overexpression the EZH1 gene inhibited HK-2 cell apoptosis, reduced ROS levels, and down-regulated the expressions of IL-1beta, IL-6, TNF-alpha, Bax and Cyt C mRNA and protein, and increased the expressions of Bcl-2 and NFKBIA, CXCL8 and cyclin D1, indicating that overexpression of EZH1 suppressed NF-kappaB signaling in aristolochic acid-injured HK-2 cells. | The Effect of Overexpression of the Enhancer of Zeste Homolog 1 (EZH1) Gene on Aristolochic Acid-Induced Injury in HK-2 Human Kidney Proximal Tubule Cells In Vitro.
Wang L, Liu N, Xue X, Zhou S., Free PMC Article | 04/27/2019 |
| identification of EZH1 as a repressor of haematopoietic multipotency in the early mammalian embryo | Regulation of embryonic haematopoietic multipotency by EZH1.
Vo LT, Kinney MA, Liu X, Zhang Y, Barragan J, Sousa PM, Jha DK, Han A, Cesana M, Shao Z, North TE, Orkin SH, Doulatov S, Xu J, Daley GQ., Free PMC Article | 07/14/2018 |
| pVHL loss causes the transcriptional activation of hypoxia-inducible factor (HIF) target genes, including many genes that encode histone lysine demethylases. | HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase.
Chakraborty AA, Nakamura E, Qi J, Creech A, Jaffe JD, Paulk J, Novak JS, Nagulapalli K, McBrayer SK, Cowley GS, Pineda J, Song J, Wang YE, Carr SA, Root DE, Signoretti S, Bradner JE, Kaelin WG Jr., Free PMC Article | 03/31/2018 |
| Data show that embryonic stem cells with deletion of EZH1 or EZH2 fail to differentiate into ectoderm lineages. | PRC2 specifies ectoderm lineages and maintains pluripotency in primed but not naïve ESCs.
Shan Y, Liang Z, Xing Q, Zhang T, Wang B, Tian S, Huang W, Zhang Y, Yao J, Zhu Y, Huang K, Liu Y, Wang X, Chen Q, Zhang J, Shang B, Li S, Shi X, Liao B, Zhang C, Lai K, Zhong X, Shu X, Wang J, Yao H, Chen J, Pei D, Pan G., Free PMC Article | 01/20/2018 |
| Expression of the EZH2 homolog EZH1 is reduced in EZH2-deficient CML LICs, creating a scenario resembling complete loss of PRC2. EZH2 dependence of CML LICs raises prospects for improved therapy of TKI-resistant CML and/or eradication of disease by addition of EZH2 inhibitors | Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2.
Xie H, Peng C, Huang J, Li BE, Kim W, Smith EC, Fujiwara Y, Qi J, Cheloni G, Das PP, Nguyen M, Li S, Bradner JE, Orkin SH., Free PMC Article | 11/4/2017 |
| a hot-spot mutation in EZH1 is the second most frequent genetic alteration in autonomous thyroid adenomas; the association between EZH1 and TSHR mutations suggests a 2-hit model for the pathogenesis of these tumors, whereby constitutive activation of the cAMP pathway and EZH1 mutations cooperate to induce the hyperproliferation of thyroid cells | Recurrent EZH1 mutations are a second hit in autonomous thyroid adenomas.
Calebiro D, Grassi ES, Eszlinger M, Ronchi CL, Godbole A, Bathon K, Guizzardi F, de Filippis T, Krohn K, Jaeschke H, Schwarzmayr T, Bircan R, Gozu HI, Sancak S, Niedziela M, Strom TM, Fassnacht M, Persani L, Paschke R., Free PMC Article | 09/30/2017 |
| EZH1, SUZ12 and UXT work synergistically to regulate pathway activation in the nucleus. | The EZH1-SUZ12 complex positively regulates the transcription of NF-κB target genes through interaction with UXT.
Su SK, Li CY, Lei PJ, Wang X, Zhao QY, Cai Y, Wang Z, Li L, Wu M. | 08/5/2017 |
| The authors report a novel PRC2-Ezh1 function that utilizes Ezh1beta as an adaptive stress sensor in the cytoplasm, thus allowing postmitotic cells to maintain tissue integrity in response to environmental changes. | A cytosolic Ezh1 isoform modulates a PRC2-Ezh1 epigenetic adaptive response in postmitotic cells.
Bodega B, Marasca F, Ranzani V, Cherubini A, Della Valle F, Neguembor MV, Wassef M, Zippo A, Lanzuolo C, Pagani M, Orlando V. | 07/15/2017 |
| These evidences suggest that EZH2 and EZH1 are important in the counter-balancing mechanisms controlling proliferation/resting of lymphoid cells. The disruption of the balanced EZH2/EZH1 ratio may play important roles in the pathogenesis of lymphomas | Aberrant differential expression of EZH1 and EZH2 in Polycomb repressive complex 2 among B- and T/NK-cell neoplasms.
Abdalkader L, Oka T, Takata K, Sato H, Murakami I, Otte AP, Yoshino T. | 04/8/2017 |
| The related enzymatic subunits EZH1 and EZH2 undergo an expression switch during blood cell development. | Developmental control of polycomb subunit composition by GATA factors mediates a switch to non-canonical functions.
Xu J, Shao Z, Li D, Xie H, Kim W, Huang J, Taylor JE, Pinello L, Glass K, Jaffe JD, Yuan GC, Orkin SH., Free PMC Article | 04/18/2015 |
| Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) | MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer.
Zhang X, Yang H, Lee JJ, Kim E, Lippman SM, Khuri FR, Spitz MR, Lotan R, Hong WK, Wu X., Free PMC Article | 12/5/2010 |
| EZH1 maintains repressive chromatin through different mechanisms. | Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms.
Margueron R, Li G, Sarma K, Blais A, Zavadil J, Woodcock CL, Dynlacht BD, Reinberg D., Free PMC Article | 01/21/2010 |